| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 3, 2019
Salt Lake City, Utah – October 3, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
-
Sep 19, 2019Company will host booth to introduce and promote mosquito abatement products to midwestern states in Tulsa, OK on Sept 19-20
Salt Lake City, Utah – September 19, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
-
Sep 4, 2019Expansion to include increased royalties and cover additional applications for Company’s technology platform
Salt Lake City, Utah – September 4, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
-
Aug 28, 2019
Salt Lake City, Utah – August 28, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
-
Aug 21, 2019Event to include demos and training for distributors and end-users of Company’s products
Salt Lake City, Utah – August 21, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
-
Aug 14, 2019Q2 revenue reflects increase over Q1, as US sales of mosquito abatement products and AgBio primer design services gain momentum
Salt Lake City, Utah – August 14, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
-
Aug 1, 2019Company’s booth will promote infectious disease products and technology applications for NGS, liquid biopsy, and SNP differentiation
Salt Lake City, Utah – August 1, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Jul 30, 2019
Salt Lake City, Utah – July 30, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Jul 18, 2019
Salt Lake City, Utah – July 18, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Jul 11, 2019
Salt Lake City, Utah – July 11, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Jun 27, 2019
Salt Lake City, Utah – June 27, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Jun 25, 2019
Salt Lake City, Utah – June 25, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
May 22, 2019
Salt Lake City, Utah – May 22, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
May 15, 2019
Salt Lake City, Utah – May 15, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Apr 30, 2019Method includes proprietary, single-step closed-tube NGS library prep in 3 hours or less
Salt Lake City, Utah – April 30, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Apr 16, 2019CoSara Diagnostics facility to be among the first of its kind in India
Salt Lake City, Utah – April 16, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Apr 2, 2019
Salt Lake City, Utah – April 02, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Mar 14, 2019Conference hosted at US corporate headquarters to include training for distributors and end-users of Company’s diagnostic, research, and vector-control products
Salt Lake City, Utah – March 14, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Mar 7, 2019Logix Smart™ ZDC Test now available for export from the United States as a CE-marked IVD
Salt Lake City, Utah – March 7, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Feb 26, 2019Company’s multiplexed Logix Smart™ ZDC Test to be available for purchase with CE mark in March 2019
Salt Lake City, Utah – February 26, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
-
Feb 22, 2019
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Feb 21, 2019Trainings will be conducted for staff and customers of Laboratorios Franja, including demonstrations of Company’s vector control products
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Feb 4, 2019
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today...
-
Jan 30, 2019Transaction included $3M of preferred shares, and the elimination of $2M of debt
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Jan 30, 2019
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today...
-
Jan 23, 2019Presentation coincided with launch of a private-label CoPrimer Product
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Jan 10, 2019Company Senior Research Scientist will be a guest speaker of LGC, Biosearch
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Dec 14, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Nov 30, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Nov 26, 2018Trainings will be conducted for staff and customers of Laboratorios Franja, followed by launch of Company’s products in DR
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
-
Oct 30, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, and...
-
Oct 29, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, and...
-
Oct 18, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Oct 9, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Sep 20, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Sep 13, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Aug 21, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Aug 10, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Jul 25, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Jul 17, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
-
Jun 11, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
-
Jun 5, 2018Proof of concept study successful in demonstrating potential SNP multiplexing applications
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
-
Jun 1, 2018CoPrimers™ used in proof of concept evaluation
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that...
-
Apr 16, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostic testing, announced...
-
Apr 6, 2018CODX updates on initial six months as a public company
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced the...
-
Mar 22, 2018Project moving forward on schedule, with production to begin in Q3 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an...
-
Feb 28, 2018
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
-
Feb 21, 2018Shipment includes 10,000 tests to be sold as Research Use Only by Joint Venture
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
-
Jan 30, 2018Program received enthusiastically by regional Ministries of Health
SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced...
-
Dec 19, 2017Laboratory will meet CGMP Requirements of FDA; Will be BSL-2 to allow enhanced in-house verification and validation activities
SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today...